Literature DB >> 29409888

Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base.

Jing Wu1, Natalie Neale2, Yuqian Huang1, Harrison X Bai3, Xuejun Li4, Zishu Zhang5, Giorgos Karakousis6, Raymond Huang7, Paul J Zhang8, Lei Tang9, Bo Xiao10, Li Yang11.   

Abstract

BACKGROUND: It is becoming increasingly common to incorporate chemotherapy (CT) with radiotherapy (RT) in the treatment of low-grade gliomas (LGGs) after surgical resection. However, there is a lack of literature comparing survival of patients who underwent RT or CT alone.
METHODS: The U.S. National Cancer Data Base was used to identify patients with histologically confirmed, World Health Organization grade 2 gliomas who received either RT alone or CT alone after surgery from 2004 to 2013. Overall survival (OS) was evaluated by Kaplan-Meier analysis, multivariable Cox proportional hazard regression, and propensity-score-matched analysis.
RESULTS: In total, 2253 patients with World Health Organization grade 2 gliomas were included, of whom 1466 (65.1%) received RT alone and 787 (34.9%) CT alone. The median OS was 98.9 months for the RT alone group and 125.8 months for the CT alone group. On multivariable analysis, CT alone was associated with a significant OS benefit compared with RT alone (hazard ratio [HR], 0.405; 95% confidence interval, 0.277-0.592; P < 0.001). On subgroup analyses, the survival advantage of CT alone over RT alone persisted across all age groups, and for the subtotal resection and biopsy groups, but not in the gross total resection group. In propensity-score-matched analysis, CT alone still showed significantly improved OS compared with RT alone (HR, 0.612; 95% confidence interval, 0.506-0.741; P < 0.001).
CONCLUSIONS: Our results suggest that CT alone was independently associated with longer OS compared with RT alone in patients with LGGs who underwent surgery.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Low-grade glioma; National Cancer Data Base (NCDB); Radiotherapy; Survival

Mesh:

Year:  2018        PMID: 29409888     DOI: 10.1016/j.wneu.2018.01.163

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  8 in total

Review 1.  What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?

Authors:  Roberta Rudà; Francesco Bruno; Riccardo Soffietti
Journal:  Curr Treat Options Neurol       Date:  2018-07-04       Impact factor: 3.598

2.  The Survival Benefits of Surgical Resection and Adjuvant Therapy for Patients With Brainstem Glioma.

Authors:  Zhuoyi Liu; Songshan Feng; Jing Li; Hui Cao; Jun Huang; Fan Fan; Li Cheng; Zhixiong Liu; Quan Cheng
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

3.  Clinical characteristics and disease-specific prognostic nomogram for primary gliosarcoma: a SEER population-based analysis.

Authors:  Song-Shan Feng; Huang-Bao Li; Fan Fan; Jing Li; Hui Cao; Zhi-Wei Xia; Kui Yang; Xiao-San Zhu; Ting-Ting Cheng; Quan Cheng
Journal:  Sci Rep       Date:  2019-07-24       Impact factor: 4.379

4.  The Epidemiological Characteristics and Prognostic Factors of Low-Grade Brainstem Glioma: A Real-World Study of Pediatric and Adult Patients.

Authors:  Zhuoyi Liu; Songshan Feng; Jing Li; Hui Cao; Jun Huang; Fan Fan; Li Cheng; Zhixiong Liu; Quan Cheng
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

5.  The effects of tumor size and postoperative radiotherapy for patients with adult low-grade (WHO grade II) infiltrative supratentorial astrocytoma/oligodendroglioma: A population-based and propensity score matched study.

Authors:  Dong-Dong Lin; Xiang-Yang Deng; Dong-Dong Zheng; Cheng-Hui Gu; Li-Sheng Yu; Shang-Yu Xu; Dan-Dong Li; Jun-Hao Fang; Bo Yin; Han-Song Sheng; Jian Lin; Xiao-Lei Zhang; Nu Zhang
Journal:  Cancer Med       Date:  2018-10-30       Impact factor: 4.452

6.  Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.

Authors:  Amélie Darlix; Emmanuel Mandonnet; Christian F Freyschlag; Daniel Pinggera; Marie-Therese Forster; Martin Voss; Joachim Steinbach; Carmel Loughrey; John Goodden; Giuseppe Banna; Concetta Di Blasi; Nicolas Foroglou; Andreas F Hottinger; Marie-Hélène Baron; Johan Pallud; Hugues Duffau; Geert-Jan Rutten; Fabien Almairac; Denys Fontaine; Luc Taillandier; Catarina Pessanha Viegas; Luisa Albuquerque; Gord von Campe; Tadeja Urbanic-Purkart; Marie Blonski
Journal:  Neurooncol Pract       Date:  2018-12-13

7.  Survival Risk Prediction Models of Gliomas Based on IDH and 1p/19q.

Authors:  Han Zou; Chang Li; Siyi Wanggou; Xuejun Li
Journal:  J Cancer       Date:  2020-04-27       Impact factor: 4.207

8.  Lcn2-derived Circular RNA (hsa_circ_0088732) Inhibits Cell Apoptosis and Promotes EMT in Glioma via the miR-661/RAB3D Axis.

Authors:  Tao Jin; Mingfa Liu; Yan Liu; Yuanzhi Li; Zhennan Xu; Haoqi He; Jie Liu; Yuxuan Zhang; Yiquan Ke
Journal:  Front Oncol       Date:  2020-02-21       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.